Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company, will be presenting at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available on January 10 at 7:00 AM ET on their website. Imara is focused on developing therapeutics for rare genetic disorders, advancing tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia, and IMR-261 as an Nrf2 activator.

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.

A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10^th and will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for sickle cell disease and beta-thalassemia and preclinical development for heart failure with preserved ejection fraction, or HFpEF. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What conference will Imara Inc. be presenting at in January 2022?

Imara Inc. will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022.

When will Imara's presentation be available for viewing?

The pre-recorded presentation will be available on January 10, 2022, at 7:00 AM ET.

What is Imara Inc. focused on developing?

Imara Inc. is developing novel therapeutics for rare inherited genetic disorders of hemoglobin and other serious diseases.

What are the main drugs Imara is advancing?

Imara is advancing tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia, and IMR-261 as an Nrf2 activator.